Observers are unsure whether to call it a ‘biosame’ or an ‘authorized biosimilar’, but Japanese drugmaker Kyowa Hakko Kirin has had a copy of its own biologic a 17 August 2018
London-listed Jordanian drugmaker Hikma Pharmaceuticals has signed a licensing agreement with Spanish pharma firm Laboratorios Farmaceúticos Rovi for its enoxap 24 April 2018
Samsung Bioepis has had its Biologics License Application for SB3, a biosimilar referencing Roche’s big-selling cancer drug Herceptin (trastuzumab), accepted by 20 December 2017
Swiss drugmaker Roche is suing Pfizer, the world’s biggest pharma company, over alleged infringements of patents relating to the cancer drug Herceptin (trastuzu 22 November 2017
India’s Biocon and Netherlands-incorporated Mylan have suffered a setback in their bid for US FDA approval for MYL-1401H, the firms’ jointly-developed Neulasta 10 October 2017
The trade group representing manufacturers of generic and biosimilar medicines in Europe has sounded a warning about the ‘unsustainably low’ prices being paid f 29 September 2017
Amgen and Chinese drugmaker Simcere Pharmaceutical Group have signed an exclusive agreement to co-develop and commercialize four biosimilars in China. The colla 28 September 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.